This week we discussed aprocitentan, another endothelin receptor antagonist, this time being explored in the resistant hypertension arena - you know the #TenTweetNephJC drill, if you want a rapid catch up then here’s your place!
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.
2025 was rich in successful stories. Here are the top 10 that impressed our audience.
This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.
This week we discussed aprocitentan, another endothelin receptor antagonist, this time being explored in the resistant hypertension arena - you know the #TenTweetNephJC drill, if you want a rapid catch up then here’s your place!
Would a new drug option for resistant hypertension get you excited? How about a superior trial design?
— Nephrology Journal Club (@NephJC) December 9, 2022
Time to learn about PRECISION - our twitter journal club had 720 tweets, but you can catch the highlights quickly with the regular #TenTweetNephJC thread👇 pic.twitter.com/YH1P4rCIRG